Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Por:
Molica, M, Miralles, G, Dillon, R, Annunziata, M, Basheer, F, Bergua, JM, Calmet, FV, Campbell, V, Cetin, D, Cimino, G, Ciotti, G, Corbingi, A, De Fazio, L, Erol, HA, Federico, V, Gil, C, Gulu, YM, Malcorra, AB, Mariani, S, Mazzone, C, Mulè, A, Musuraca, G, Khan, A, Norata, M, O'Nions, J, Palumbo, FE, Papayannidis, C, Piccioni, AL, Rubio, MTO, Sanchez-Tovar, J, Serin, I, Serrao, A, Sevindik, OG, Sucato, G, Urbano, MA, Vetro, C, Vives, S, Rossi, M, Martelli, MP, Montesinos, P, Othman, J and Perrone, S
Publicada:
1 ene 2026
Ahead of Print:
1 nov 2025
Resumen:
Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following >= 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3-mutated AML who received gilteritinib as third-line or beyond between August 2017 and March 2024 across centers in Italy, Spain, the United Kingdom, and Turkey. The primary endpoint was overall survival (OS). Secondary endpoints included overall response rate (ORR), composite complete remission (cCR), duration of response. Among the 171 patients, 84% carried FLT3-ITD mutations and 26% had received >= 3 prior lines of therapy. The cCR rate was 28%, and ORR was 47%. Patients who were younger and presented with relapsed (vs. refractory) disease had better outcomes. Prior exposure to venetoclax or allogeneic hematopoietic stem cell transplantation (HSCT) was associated with inferior response. Gilteritinib enabled HSCT in 12% of patients. Median OS was 7.1 months (95% CI, 5.9-10.1), and in Cox-regression analysis was significantly improved among responders and those who underwent HSCT (median OS: 21.5 months; 95% CI, 12.8-NR). Prior venetoclax exposure was associated with shorter survival (5.7 months; 95% CI, 5.1-8.8). On multivariate analysis, previous exposure to venetoclax and FLT3 inhibitors was the strongest predictor of reduced response rates. Despite heavy pretreatment, gilteritinib retained clinically relevant activity in later-line R/R FLT3-mutated AML. Its use beyond second-line may serve as a bridge to HSCT in selected patients. Resistance mechanisms, particularly following venetoclax, remain a therapeutic challenge. These data support the continued use of gilteritinib beyond second-line and highlight the need for prospective studies to optimize sequencing strategies.
Filiaciones:
Molica, M:
Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy
Miralles, G:
Hosp Gen Elche, Alicante, Spain
Dillon, R:
Kings Coll London, Dept Med & Mol Genet, London, England
Annunziata, M:
Cardarelli Hosp, Hematol Unit, Naples, Italy
Basheer, F:
Addenbrookes Hosp, Dept Haematol, Cambridge, England
Bergua, JM:
Hosp San Pedro Alcantara, Dept Hematol, Caceres, Spain
Calmet, FV:
Hosp Univ Mutua Terrassa, Hematol Dept, Terrassa, Spain
Campbell, V:
Western Gen Hosp, Edinburgh, Scotland
Cetin, D:
Ege Univ, Sch Med, Dept Hematol, Izmir, Turkiye
Cimino, G:
Univ Perugia, Dept Med & Surg, Hematol, CREO, Perugia, Italy
Azienda Osped Perugia, Perugia, Italy
Ciotti, G:
Ist Oncol Veneto IOV IRCCS, UOC Oncohematol, Dept Oncol, Padua, Italy
Corbingi, A:
Polo Univ Pontino, S M Goretti Hosp, Dept Hematol, Latina, Italy
De Fazio, L:
Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy
Erol, HA:
Kocaeli Univ, Fac Med, Dept Hematol, Kocaeli, Turkiye
Federico, V:
Vito Fazzi Hosp, Hematol & Transplant Unit, Lecce, Italy
Gil, C:
Hosp Gen Alicante, Alicante, Spain
Gulu, YM:
Gaziantep City Hosp, Dept Hematol, Gaziantep, Turkiye
Malcorra, AB:
Hosp Univ Cruces, San Vicente De Barakaldo, Bizkaia, Spain
Mariani, S:
Sapienza Univ Rome, Univ Hosp St Andrea, Dept Hematol, Rome, Italy
Mazzone, C:
St Eugenio Hosp, Hematol Unit, Rome, Italy
Mulè, A:
AOOR Villa Sofia Cervello, Hematol Unit, Palermo, Italy
Khan, A:
Leeds Teaching Hosp Trust, Dept Haematol, Leeds, England
O'Nions, J:
Univ Coll London Hosp NHS Fdn Trust, London, England
Palumbo, FE:
AOU Policlin G RodolicoSan Marco, Div Hematol, Catania, Italy
Papayannidis, C:
IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
Piccioni, AL:
San Giovanni Addolorata Hosp, Dept Hematol, Rome, Italy
Rubio, MTO:
Hosp Clin Univ Lorenzo Blesa, Zaragoza, Spain
Sanchez-Tovar, J:
Hosp Rio Carrion, Complejo Asistencial Palencia, Palencia, Spain
Serin, I:
Istanbul Basaksehir Cam & Sakura City Hosp, Dept Hematol, Istanbul, Turkiye
Serrao, A:
San Camillo Hosp, Hematol Unit, Rome, Italy
Sevindik, OG:
Istanbul Florence Nightingale Hosp, Clin Hematol, Istanbul, Turkiye
Sucato, G:
Univ Hosp Paolo Giaccone, Hematol Unit, Palermo, Italy
Urbano, MA:
A Perrino Hosp, Hematol Unit, Brindisi, Italy
Vetro, C:
Paracelsus Med Univ PMU, Hosp Bolzano SABES ASDAA, Teaching Hosp, Hematol & Bone Marrow Transplantat Unit BMTU, Bolzano, Italy
:
Hosp U Germans Trias i Pujol ICO, Badalona, Spain
Rossi, M:
Azienda Univ Osped Renato Dulbecco, Dept Hematol Oncol, Catanzaro, Italy
Martelli, MP:
Univ Perugia, Dept Med & Surg, Hematol, CREO, Perugia, Italy
Azienda Osped Perugia, Perugia, Italy
Montesinos, P:
La Fe Univ & Polytech Hosp, Hematol Dept, Valencia, Spain
Othman, J:
Kings Coll London, Dept Med & Mol Genet, London, England
Perrone, S:
Polo Univ Pontino, S M Goretti Hosp, Dept Hematol, Latina, Italy
hybrid
|